Key Highlights

● NextCure shares have fallen sharply, most recently closing at $6.25, down 7.82%, as the market continues repricing the stock around its pending Reverse merger with Avere Therapeutics.

● Under the merger terms, pre-merger Avere stockholders will own approximately 98.11% of the combined company, while pre-merger NextCure stockholders retain only about 1.89%.

● NextCure halted U.S. expansion of its SIM0505 antibody-drug conjugate program and is winding down that trial, a decision the company said was not based on any negative safety or efficacy finding.

● The deal is paired with a private Placement reported at approximately $320 million to fund Avere's lead asset, AVR-001, a once-weekly oral IL-23 therapy, with a third-quarter 2026 closing targeted.

NextCure (NASDAQ:NXTC), the Beltsville, Maryland biotech founded on immuno-oncology research, has seen its shares weaken sharply as investors digest a transformative corporate transaction that effectively ends the company's independent immunotherapy story. The stock closed at $6.25 on 20 August 2026, down 7.82% on the day, within a wide 52-week range of $1.55 to $15.74. With a market Capitalization of roughly $29 million, NextCure now trades largely as a function of the pending deal rather than its legacy pipeline.

The ticker NXTC corresponds to NextCure on the Nasdaq. In July 2026 the company announced a reverse merger with privately held Avere Therapeutics, and much of the recent share-price behavior reflects the market repricing NextCure's Equity toward the small residual stake its existing holders will retain in the combined entity.

The likely trigger: a reverse merger that dilutes legacy holders to a sliver

The dominant, verifiable catalyst is the Avere transaction. Under the terms disclosed in NextCure's filings, pre-merger Avere stockholders, including investors in an accompanying private placement, will own approximately 98.11% of the combined company, while pre-merger NextCure stockholders will retain only about 1.89%. The combined entity is to be renamed Avere Therapeutics and led by Avere's president and chief executive, with a board dominated by Avere designees. In substance, this is a reverse Takeover in which NextCure's public listing becomes the vehicle for Avere's programs.

That ownership split is the central fact for investors. When existing holders are reduced to under 2% of a combined company, the Market Value of the legacy shares collapses toward the value of whatever residual rights those holders receive. The specific 21 August decline has not been tied to a discrete same-day announcement, and the precise trigger for the daily move has not been definitively established; the more durable explanation is the ongoing repricing of NextCure equity around the merger economics.

What happens to NextCure's immunotherapy pipeline

For the "immunotherapy story," the transaction is decisive rather than a mere setback. The combined company's focus shifts to Avere's lead asset, AVR-001, a once-weekly oral IL-23 therapy aimed at immune-mediated disease, a program outside NextCure's historical immuno-oncology franchise. NextCure's own clinical Assets are being wound down or handed off. The company halted U.S. expansion of its SIM0505 antibody-drug conjugate program, instructing clinical sites to stop screening, consenting, enrolling and dosing new patients, and said it plans to wind down that study while stressing the decision was "not based on any negative safety or efficacy finding." On the LNCB74 program, NextCure opted out of cost-sharing, with the companies in discussions about potential continuation under partner LigaChem.

To preserve some upside for legacy holders, the deal provides contingent value rights entitling pre-merger NextCure stockholders to 90% of gross proceeds from any sale of legacy assets during the CVR term. Such rights, however, are inherently uncertain: they pay out only if the wound-down or transferred programs are eventually sold on economic terms, and their value cannot be known in advance. The company also flagged roughly $1.9 million in one-time restructuring charges in the third quarter of 2026, primarily severance and termination costs affecting a substantial majority of its employees, a clear signal that the legacy organization is being dismantled as part of the combination.

The financing that underpins the deal

The transaction is paired with a substantial private placement to fund Avere's pipeline. NextCure's filings describe a private placement providing approximately $320 million through the sale of Avere securities and pre-funded warrants, with closing conditioned on minimum proceeds of at least $150 million. Reporting around the announcement referenced larger aggregate financing figures tied to the combined company's plans, and a subsequent August release referenced a $500 million private placement to support AVR-001; investors should rely on the definitive proxy and merger documents for the final, reconciled terms. Regardless of the precise headline number, the scale of new capital flowing to Avere holders, not to legacy NextCure shareholders, reinforces why the existing equity has repriced lower.

Why investors are concerned

The concern is structural and hard to escape. A reverse merger that leaves incumbent shareholders with under 2% of the combined company represents near-total dilution of the legacy equity. The programs that defined NextCure as an immuno-oncology company are being discontinued or transferred, the workforce is being cut, and the strategic direction is being handed to a different management team pursuing a different therapeutic area. For anyone who owned NXTC as a bet on its cancer-immunotherapy pipeline, the transaction is the end of that thesis, softened only by the contingent value rights tied to uncertain future asset sales.

At the same time, the deal brings a well-capitalized clinical program and a fresh strategy into the public vehicle, which is why the shares retain value rather than collapsing entirely. The question for holders is whether the residual stake plus the CVR is worth more or less than the market is currently assigning, a judgment that depends on the eventual closing terms and on the prospects for AVR-001.

What to watch next

The near-term calendar is dominated by merger mechanics. Key items include the definitive proxy statement and its reconciled financing terms, the required NextCure stockholder vote, the expected third-quarter 2026 closing, and confirmation of the new ticker and corporate name once the combination completes. Investors should also watch for any disposition of the legacy SIM0505 and LNCB74 assets that could trigger CVR payments, the finalization of restructuring charges, and early disclosures on AVR-001's development plan under the renamed company. Until the merger closes, NXTC is best understood as a stub trading on deal terms rather than as an operating immuno-oncology business. Any answer to whether the immunotherapy story faces "another setback" is, in truth, an understatement: the transaction retires that story and substitutes a new one built around Avere's oral IL-23 candidate.